Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Phenotypic implications of pathogenic variant types in Pompe disease

Journal of Human Genetics volume 66, pages 1089–1099 (2021)Cite this article

Subjects

Abstract

Newborn screening and therapies for Pompe disease (glycogen storage disease type II, acid maltase deficiency) will continue to expand in the future. It is thus important to determine whether enzyme activity or type of pathogenic genetic variant in GAA can best predict phenotypic severity, particularly the presence of infantile-onset Pompe disease (IOPD) versus late-onset Pompe disease (LOPD). We performed a retrospective analysis of 23 participants with genetically-confirmed cases of Pompe disease. The following data were collected: clinical details including presence or absence of cardiomyopathy, enzyme activity levels, and features of GAA variants including exon versus intron location and splice site versus non-splice site. Several combinations of GAA variant types for individual participants had significant associations with disease subtype, cardiomyopathy, age at diagnosis, gross motor function scale (GMFS), and stability of body weight. The presence of at least one splice site variant (c.546 G > C/p.T182 = , c.1076–22 T > G, c.2646 + 2 T > A, and the classic c.−32–13T > G variant) was associated with LOPD, while the presence of non-splice site variants on both alleles was associated with IOPD. Enzyme activity levels in isolation were not sufficient to predict disease subtype or other major clinical features. To extend the findings of prior studies, we found that multiple types of splice site variants beyond the classic c.−32–13T > G variant are often associated with a milder phenotype. Enzyme activity levels continue to have utility for supporting the diagnosis when the genetic variants are ambiguous. It is important for newly diagnosed patients with Pompe disease to have complete genetic, cardiac, and neurological evaluations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Martiniuk F, Mehler M, Pellicer A, Tzall S, La Badie G, Hobart C, et al. Isolation of a cDNA for human acid alpha-glucosidase and detection of genetic heterogeneity for mRNA in three alpha-glucosidase-deficient patients. Proc Natl Acad Sci USA. 1986;83:9641–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Pompe JC. Over idiopatische hypertrophie van het hart. Ned T Geneesk. 1932;76:304–11.

    Google Scholar 

  3. Hers HG. alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe’s disease). Biochem J. 1963;86:11–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Holmes JM, Houghton CR, Woolf AL. A Myopathy Presenting in Adult Life with Features Suggestive of Glycogen Storage Disease. J Neurol Neurosurg Psychiatry. 1960;23:302–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Zellweger H, Brown BI, McCormick WF, Tu JB. A mild form of muscular glycogenosis in two brothers with alpha-1, 4-glucosidase deficiency. Ann Paediatr. 1965;205:413–37.

    CAS  PubMed  Google Scholar 

  6. Goldstein JL, Young SP, Changela M, Dickerson GH, Zhang H, Dai J, et al. Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory. Muscle Nerve. 2009;40:32–36.

    Article  CAS  PubMed  Google Scholar 

  7. Gupta N, Kazi ZB, Nampoothiri S, Jagdeesh S, Kabra M, Puri RD, et al. Clinical and Molecular Disease Spectrum and Outcomes in Patients with Infantile-Onset Pompe Disease. J Pediatr. 2020;216:44–50 e45.

    Article  CAS  PubMed  Google Scholar 

  8. Wens SC, Kroos MA, de Vries JM, Hoogeveen-Westerveld M, Wijgerde MG, van Doorn PA, et al. Remarkably low fibroblast acid alpha-glucosidase activity in three adults with Pompe disease. Mol Genet Metab. 2012;107:485–9.

    Article  CAS  PubMed  Google Scholar 

  9. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 2000;356:397–8.

    Article  PubMed  Google Scholar 

  10. Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics. 2004;113:e448–7.

    Article  PubMed  Google Scholar 

  11. Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. 2006;149:89–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Winkel LP, Van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF, et al. Enzyme replacement therapy in late-onset Pompe’s disease: a three-year follow-up. Ann Neurol. 2004;55:495–502.

    Article  CAS  PubMed  Google Scholar 

  13. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med. 2010;362:1396–406.

    Article  PubMed  Google Scholar 

  14. Kishnani PS, Hwu WL, and Pompe Disease Newborn Screening Working, G. Introduction to the Newborn Screening, Diagnosis, and Treatment for Pompe Disease Guidance Supplement. Pediatrics. 2017;140:S1–S3.

    Article  PubMed  Google Scholar 

  15. Chien YH, Hwu WL, Lee NC. Newborn screening: Taiwanese experience. Ann Transl Med. 2019;7:281.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Momosaki K, Kido J, Yoshida S, Sugawara K, Miyamoto T, Inoue T, et al. Newborn screening for Pompe disease in Japan: report and literature review of mutations in the GAA gene in Japanese and Asian patients. J Hum Genet. 2019;64:741–55.

    Article  CAS  PubMed  Google Scholar 

  17. Elder ME, Nayak S, Collins SW, Lawson LA, Kelley JS, Herzog RW, et al. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. 2013;163:847–54 e841.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Corti M, Elder M, Falk D, Lawson L, Smith B, Nayak S, et al. B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: a Human Subject Case Study. Mol Ther Methods Clin Dev. 2014;1:14033.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Stockton DW, Kishnani P, van der Ploeg A, Llerena J Jr., Boentert M, Roberts M, et al. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start. J Neurol. 2020;267:3038–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. den Dunnen, JT. Describing Sequence Variants Using HGVS Nomenclature. In: SJ White and S Cantsilieris, editors. Genotyping: Methods and Protocols. New York, NY: Springer New York; 2017. p. 243–51.

  21. Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, et al. The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol. 2005;252:875–84.

    Article  PubMed  Google Scholar 

  22. Whitaker CH, Felice KJ, Natowicz M. Biopsy-proven alpha-glucosidase deficiency with normal lymphocyte enzyme activity. Muscle Nerve. 2004;29:440–2.

    Article  CAS  PubMed  Google Scholar 

  23. Temple JK, Dunn DW, Blitzer MG, Shapira E. The “muscular variant” of Pompe disease: clinical, biochemical and histologic characteristics. Am J Med Genet. 1985;21:597–604.

    Article  CAS  PubMed  Google Scholar 

  24. Potter JL, Robinson HB Jr., Kramer JD, Schafter IA. Apparent normal leukocyte acid maltase activity in glycogen storage disease type II (Pompe’s disease). Clin Chem. 1980;26:1914–5.

    Article  CAS  PubMed  Google Scholar 

  25. de Barsy T, Ferriere G, Fernandez-Alvarez E. Uncommon case of type II glycogenosis. Acta Neuropathol. 1979;47:245–7.

    Article  PubMed  Google Scholar 

  26. Bertagnolio B, Di Donato S, Peluchetti D, Rimoldi M, Storchi G, Cornelio F. Acid maltase deficiency in adults. Clinical, morphological and biochemical study of three patients. Eur Neurol. 1978;17:193–204.

    Article  CAS  PubMed  Google Scholar 

  27. Kroos MA, Van der Kraan M, Van Diggelen OP, Kleijer WJ, Reuser AJ, Van den Boogaard MJ, et al. Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients. J Med Genet. 1995;32:836–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Reuser AJJ, van der Ploeg AT, Chien YH, Llerena J Jr., Abbott MA, Clemens PR, et al. GAA variants and phenotypes among 1,079 patients with Pompe disease: data from the Pompe Registry. Hum Mutat. 2019;40:2146–64.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Herzog A, Hartung R, Reuser AJ, Hermanns P, Runz H, Karabul N, et al. A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations. Orphanet J Rare Dis. 2012;7:35.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Huie ML, Chen AS, Tsujino S, Shanske S, DiMauro S, Engel AG, et al. Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (−13T->G) mutation in a majority of patients and a novel IVS10 (+1GT->CT) mutation. Hum Mol Genet. 1994;3:2231–6.

    Article  CAS  PubMed  Google Scholar 

  31. Laforet P, Nicolino M, Eymard PB, Puech JP, Caillaud C, Poenaru L, et al. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology. 2000;55:1122–8.

    Article  CAS  PubMed  Google Scholar 

  32. van Capelle CI, van der Meijden JC, van den Hout JM, Jaeken J, Baethmann M, Voit T, et al. Childhood Pompe disease: clinical spectrum and genotype in 31 patients. Orphanet J Rare Dis. 2016;11:65.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Montalvo AL, Bembi B, Donnarumma M, Filocamo M, Parenti G, Rossi M, et al. Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat. 2006;27:999–1006.

    Article  CAS  PubMed  Google Scholar 

  34. Alandy-Dy J, Wencel M, Hall K, Simon J, Chen Y, Valenti E, et al. Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease. Ann Transl Med. 2019;7:276.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Kroos MA, Pomponio RJ, Hagemans ML, Keulemans JL, Phipps M, DeRiso M, et al. Broad spectrum of Pompe disease in patients with the same c.−32-13T->G haplotype. Neurology. 2007;68:110–5.

    Article  CAS  PubMed  Google Scholar 

  36. Herbert M, Case LE, Rairikar M, Cope H, Bailey L, Austin SL, et al. Early-onset of symptoms and clinical course of Pompe disease associated with the c.-32-13T>G variant. Mol Genet Metab. 2019;126:106–16.

    Article  CAS  PubMed  Google Scholar 

  37. Zampieri S, Buratti E, Dominissini S, Montalvo AL, Pittis MG, Bembi B, et al. Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients’ phenotypes. Eur J Hum Genet. 2011;19:422–31.

    Article  CAS  PubMed  Google Scholar 

  38. Hermans MM, van Leenen D, Kroos MA, Beesley CE, Van Der Ploeg AT, Sakuraba H, et al. Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat. 2004;23:47–56.

    Article  CAS  PubMed  Google Scholar 

  39. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, Infantile-Onset Pompe Disease Natural History Study, G. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148:671–6.

    Article  PubMed  Google Scholar 

  40. Bali DS, Tolun AA, Goldstein JL, Dai J, Kishnani PS. Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid alpha-glucosidase activity. Muscle Nerve. 2011;43:665–70.

    Article  CAS  PubMed  Google Scholar 

  41. Hahn A, Schanzer A. Long-term outcome and unmet needs in infantile-onset Pompe disease. Ann Transl Med. 2019;7:283.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017;264:621–30.

    Article  CAS  PubMed  Google Scholar 

  43. Peng SS, Hwu WL, Lee NC, Tsai FJ, Tsai WH, Chien YH. Slow, progressive myopathy in neonatally treated patients with infantile-onset Pompe disease: a muscle magnetic resonance imaging study. Orphanet J Rare Dis. 2016;11:63.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Prater SN, Patel TT, Buckley AF, Mandel H, Vlodavski E, Banugaria SG, et al. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy. Orphanet J Rare Dis. 2013;8:90.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Desai AK, Kazi ZB, Bali DS, Kishnani PS. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy. Mol Genet Metab Rep. 2019;20:100475.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Elmallah MK, Falk DJ, Nayak S, Federico RA, Sandhu MS, Poirier A, et al. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Mol Ther. 2014;22:702–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Falk DJ, Mah CS, Soustek MS, Lee KZ, Elmallah MK, Cloutier DA, et al. Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease. Mol Ther. 2013;21:1661–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. McCall AL, Stankov SG, Cowen G, Cloutier D, Zhang Z, Yang L, et al. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy. Curr Gene Ther. 2019;19:197–207.

    Article  CAS  PubMed  Google Scholar 

  49. Todd AG, McElroy JA, Grange RW, Fuller DD, Walter GA, Byrne BJ, et al. Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease. Ann Neurol. 2015;78:222–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Colella P, Sellier P, Costa Verdera H, Puzzo F, van Wittenberghe L, Guerchet N, et al. AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice. Mol Ther Methods Clin Dev. 2019;12:85–101.

    Article  CAS  PubMed  Google Scholar 

  51. Lim JA, Yi H, Gao F, Raben N, Kishnani PS, Sun B. Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid alpha-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease. Mol Ther Methods Clin Dev. 2019;12:233–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Han SO, Li S, Everitt JI, Koeberl DD. Salmeterol with Liver Depot Gene Therapy Enhances the Skeletal Muscle Response in Murine Pompe Disease. Hum Gene Ther. 2019;30:855–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Cagin U, Puzzo F, Gomez MJ, Moya-Nilges M, Sellier P, Abad C, et al. Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid alpha-Glucosidase. Mol Ther. 2020;28:2056–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Stok M, de Boer H, Huston MW, Jacobs EH, Roovers O, Visser TP, et al. Lentiviral Hematopoietic Stem Cell Gene Therapy Corrects Murine Pompe Disease. Mol Ther Methods Clin Dev. 2020;17:1014–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Corti M, Liberati C, Smith BK, Lawson LA, Tuna IS, Conlon TJ, et al. Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease. Hum Gene Ther Clin Dev. 2017;28:208–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Smith BK, Collins SW, Conlon TJ, Mah CS, Lawson LA, Martin AD, et al. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther. 2013;24:630–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Bodamer OA, Scott CR, Giugliani R, Pompe Disease Newborn Screening Working, G. Newborn Screening for Pompe Disease. Pediatrics. 2017;140:S4–S13.

    Article  PubMed  Google Scholar 

  58. Boentert M, Florian A, Drager B, Young P, Yilmaz A. Pattern and prognostic value of cardiac involvement in patients with late-onset pompe disease: a comprehensive cardiovascular magnetic resonance approach. J Cardiovasc Magn Reson. 2016;18:91.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Herbert M, Cope H, Li JS, Kishnani PS. Severe Cardiac Involvement Is Rare in Patients with Late-Onset Pompe Disease and the Common c.−32-13T>G Variant: implications for Newborn Screening. J Pediatr. 2018;198:308–12.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Stephanie M. Salabarria, BHSc for help in accessing clinical and genetic data.

Author information

Author notes

  1. Zara Zaidi

    Present address: Nicklaus Children’s Hospital, Miami, FL, USA

Authors and Affiliations

  1. Division of Pediatric Neurology, Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL, USA

    Manuel A. Viamonte & Peter B. Kang

  2. Department of Pediatrics, UCLA Health / Mattel Children’s Hospital, Los Angeles, CA, USA

    Manuel A. Viamonte

  3. Department of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, Gainesville, FL, USA

    Stephanie L. Filipp & Matthew J. Gurka

  4. Powell Gene Therapy Center and Child Health Research Institute, Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL, USA

    Zara Zaidi & Barry J. Byrne

  5. Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA

    Peter B. Kang

  6. Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, MN, USA

    Peter B. Kang

  7. Institute for Translational Neuroscience, University of Minnesota Medical School, Minneapolis, MN, USA

    Peter B. Kang

Authors
  1. Manuel A. Viamonte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephanie L. Filipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zara Zaidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matthew J. Gurka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Barry J. Byrne
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter B. Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter B. Kang.

Ethics declarations

Conflict of interest

Dr MAV was supported in part by an unrestricted educational fellowship from Sanofi Genzyme. Ms SLF reports no disclosures. Dr ZZ reports no disclosures. Dr MJG reports no disclosures. Dr BJB is a member of the Pompe Registry Scientific Advisory Board, and has received grant support from Sanofi Genzyme and Amicus Therapeutics. Dr PBK was the uncompensated grantee of the unrestricted fellowship from Sanofi Genzyme that supported Dr MAV. He has served as a consultant for AveXis and ChromaDex, and on an advisory board for Sarepta Therapeutics. This study was supported in part by an unrestricted educational fellowship from Sanofi Genzyme (2015–2017). Neither Sanofi Genzyme nor any individuals or organizations employed/contracted by Sanofi Genzyme participated in study design, data collection, data analysis, drafting of the paper writing, editing of the paper, or decision to submit this paper for publication.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Viamonte, M.A., Filipp, S.L., Zaidi, Z. et al. Phenotypic implications of pathogenic variant types in Pompe disease. J Hum Genet 66, 1089–1099 (2021). https://doi.org/10.1038/s10038-021-00935-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s10038-021-00935-9

This article is cited by

Search

Advanced search

Quick links